Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

Europe digital biomarkers market accounted for $118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.
Highlighted with 42 tables and 67 figures, this 145-page report “Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country.

Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Data Collection Tools
• Digital Platforms
• Mobile Apps
• Desktop-based Software
• Wearables
• Biosensors
Data Integration Systems

Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cardiovascular Diseases
Neurodegenerative Disorders
• Parkinson’s Disease
• Multiple Sclerosis
• Alzheimer’s Disease
Sleep and Movement Diseases
Psychiatric Disorders
Chronic Pain
Gastrointestinal Diseases
Diabetes
Respiratory Conditions
Other Diseases

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Wellness
• Disease Diagnosis
• Personalised Medication
• Drug Discovery and Development

Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Novel Digital Biomarkers
• Original Digital Biomarkers
• Approved Digital Biomarkers

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Biopharmaceutical Companies & Labs
• Healthcare Providers
• Insurance Payers

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Netherlands
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Actigraph LLC
Akili Interactive Labs
AliveCor Inc
Altoida Inc
Amgen Inc
Bayer AG
Biogen Inc
Cambridge Cognition Plc
Eli Lilly and Company
Evidation Health, Inc.
F. Hoffmann-La Roche Ltd
Fitbit Inc
GlaxoSmithKline Plc
Happify Health
Human API
IXICO Plc
Koninklijke Philips N.V.
Medical Care Corporation
Medopad Ltd
Mindstrong Health
Neurotrack Technology, Inc
Novartis International AG
Pfizer Inc.
Quanterix Corporation
Sanofi S.A.
The Takeda Pharmaceuticals Company Limited
Verily Life Sciences
Winterlight Labs Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)